Jiang Zhong PharmaceuticalLtd Past Earnings Performance
Past criteria checks 5/6
Jiang Zhong PharmaceuticalLtd has been growing earnings at an average annual rate of 9.1%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 17.1% per year. Jiang Zhong PharmaceuticalLtd's return on equity is 16.6%, and it has net margins of 17.1%.
Key information
9.1%
Earnings growth rate
8.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 17.1% |
| Return on equity | 16.6% |
| Net Margin | 17.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Jiang Zhong PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,273 | 733 | 1,730 | 135 |
| 31 Dec 23 | 4,390 | 708 | 1,837 | 133 |
| 30 Sep 23 | 4,077 | 681 | 1,806 | 98 |
| 30 Jun 23 | 4,208 | 651 | 1,924 | 102 |
| 31 Mar 23 | 4,197 | 653 | 1,879 | 99 |
| 31 Dec 22 | 3,885 | 598 | 1,715 | 100 |
| 30 Sep 22 | 3,811 | 559 | 1,713 | 113 |
| 30 Jun 22 | 3,509 | 591 | 1,494 | 99 |
| 31 Mar 22 | 3,127 | 530 | 1,338 | 96 |
| 31 Dec 21 | 2,874 | 506 | 1,196 | 88 |
| 30 Sep 21 | 2,644 | 528 | 1,070 | 70 |
| 30 Jun 21 | 2,549 | 510 | 1,028 | 66 |
| 31 Mar 21 | 2,594 | 502 | 1,038 | 66 |
| 31 Dec 20 | 2,441 | 474 | 964 | 56 |
| 30 Sep 20 | 2,481 | 480 | 997 | 51 |
| 30 Jun 20 | 2,467 | 482 | 976 | 50 |
| 31 Mar 20 | 2,437 | 468 | 1,013 | 46 |
| 31 Dec 19 | 2,449 | 464 | 1,033 | 48 |
| 30 Sep 19 | 2,167 | 498 | 814 | 45 |
| 30 Jun 19 | 2,001 | 494 | 728 | 41 |
| 31 Mar 19 | 1,832 | 481 | 623 | 36 |
| 31 Dec 18 | 1,755 | 470 | 597 | 30 |
| 30 Sep 18 | 1,731 | 450 | 629 | 26 |
| 30 Jun 18 | 1,764 | 436 | 658 | 31 |
| 31 Mar 18 | 1,778 | 425 | 698 | 27 |
| 31 Dec 17 | 1,747 | 418 | 681 | 23 |
| 30 Sep 17 | 1,764 | 438 | 656 | 12 |
| 30 Jun 17 | 1,555 | 386 | 591 | 0 |
| 31 Mar 17 | 1,497 | 374 | 561 | 0 |
| 31 Dec 16 | 1,548 | 372 | 636 | 0 |
| 30 Sep 16 | 1,805 | 401 | 651 | 0 |
| 30 Jun 16 | 2,150 | 424 | 731 | 0 |
| 31 Mar 16 | 2,455 | 411 | 809 | 0 |
| 31 Dec 15 | 2,597 | 367 | 795 | 0 |
| 30 Sep 15 | 2,664 | 332 | 839 | 0 |
| 30 Jun 15 | 2,763 | 308 | 942 | 0 |
| 31 Mar 15 | 2,757 | 275 | 973 | 0 |
| 31 Dec 14 | 2,834 | 265 | 1,046 | 0 |
| 30 Sep 14 | 2,952 | 188 | 1,123 | 0 |
| 30 Jun 14 | 2,872 | 154 | 1,034 | 0 |
| 31 Mar 14 | 2,829 | 142 | 945 | 0 |
| 31 Dec 13 | 2,778 | 172 | 813 | 0 |
| 30 Sep 13 | 2,893 | 215 | 788 | 0 |
| 30 Jun 13 | 2,948 | 232 | 845 | 0 |
Quality Earnings: 600750 has high quality earnings.
Growing Profit Margin: 600750's current net profit margins (17.1%) are higher than last year (15.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600750's earnings have grown by 9.1% per year over the past 5 years.
Accelerating Growth: 600750's earnings growth over the past year (12.1%) exceeds its 5-year average (9.1% per year).
Earnings vs Industry: 600750 earnings growth over the past year (12.1%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 600750's Return on Equity (16.6%) is considered low.